Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line RiPAD+C with Velcade for mantle cell lymphoma in older adults
2006-004768-30Phase 2Completed
- Sponsor
- Goelams
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and rituximab in mantle cell lymphoma (MCL), sponsored by Goelams. Primary endpoint: Overall response rate after 4 cycles. Started Feb 2007; status: completed.
02
Drugs
bortezomibrituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2006-004768-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004768-30.